Jia Liao, Ramin Ebrahimi, Zhiyu Ling, Christian Meyer, Martin Martinek, Philipp Sommer, Piotr Futyma, Davide Di Vece, Alexandra Schratter, Willem-Jan Acou, Lin Zhu, Márcio G Kiuchi, Shaowen Liu, Yuehui Yin, Helmut Pürerfellner, Christian Templin, Shaojie Chen
OBJECTIVE: We aimed to assess the effect of SGLT2i on arrhythmias by conducting a meta-analysis using data from randomized controlled trials(RCTs). BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardioprotective effects via multiple mechanisms that may also contribute to decrease arrhythmias risk. METHODS: We searched in databases (PubMed, Embase, Cochrane Library, and clinicaltrials.gov) up to April 2023. RCTs comparing SGLT2i with placebo were included...
February 24, 2024: Cardiovascular Diabetology